sarm1-inhibitors-neurodegeneration

📖 Wiki Page

therapeutic1088 wordssynced 2026-04-02

SARM1 Inhibitors for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">sarm1-inhibitors-neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>sarm1-inhibitors-neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Introduction

Sarm1 Inhibitors For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

SARM1 inhibitors represent a breakthrough therapeutic approach for preventing axon degeneration in neurodegenerative diseases. SARM1 (Sterile Alpha and TIR Motif Containing 1) is the central executioner of programmed axon degeneration, and pharmacological inhibition of its NADase activity offers neuroprotection across multiple disease contexts. [@figley2020]

Overview

...

SARM1 Inhibitors for Neurodegeneration

Introduction

Overview

Mermaid diagram (expand to render)

SARM1 (Sterile Alpha and TIR Motif Containing 1) is a NAD+ degrading enzyme that acts as the central executioner of axonal degeneration. Following axonal injury or in certain neurodegenerative conditions, SARM1 triggers a catastrophic loss of cellular NAD+, leading to energy failure and axonal death. SARM1 inhibitors represent a paradigm-shifting approach to protect axons and preserve neuronal connectivity. [@chaudhry2024]

Therapeutic rationale for SARM1 inhibition: [@chaudhry2024a]

Axonal protection: Prevents the secondary degeneration that follows initial injury
Broad applicability: Relevant to traumatic brain injury, peripheral neuropathy, and neurodegenerative diseases
Mechanistic target: Directly blocks the molecular trigger of axonal collapse
Preventive potential: Could be administered prophylactically in high-risk populations

This page provides detailed coverage of SARM1 biology, the mechanism of action of emerging inhibitors, clinical development status, and therapeutic applications across neurological conditions. [@ferraiuolo2015]

Mechanism of Action

SARM1 is a NAD+ hydrolase that becomes activated following axonal injury or in disease states when the NMN/NAD+ ratio increases due to depletion of the axon survival factor NMNAT2[@osterloh2012]. Activated SARM1 triggers catastrophic depletion of axonal NAD+, leading to metabolic failure and calcium influx that destroys the axon[@figley2020]. [@xie2019]

SARM1 inhibitors target this pathway at multiple points: [@cheng2011]

Direct NADase inhibition: Small molecules that bind the TIR domain catalytic site
Allosteric modulators: Compounds that stabilize the autoinhibited conformation
NAD+ precursors: Boost axonal NAD+ levels to maintain the protective NMN/NAD+ ratio
NMN accumulation blockers: Reduce NMN availability to prevent SARM1 activation

Therapeutic Applications

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

SARM1 inhibitors have shown particular promise for preventing chemotherapy-induced peripheral neuropathy, a dose-limiting side effect of many anticancer therapies. Drugs including paclitaxel, vincristine, cisplatin, and bortezomib cause rapid depletion of NMNAT2 in peripheral axons, triggering SARM1 activation[@chaudhry2024]. [@yang2015]

Preclinical studies demonstrate that SARM1 inhibition provides robust protection against CIPN without compromising anticancer efficacy, addressing a significant unmet medical need[@chaudhry2024a]. [@quigley2024]

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron degeneration in ALS involves prominent axonal pathology, and SARM1 activation contributes to this process. Genetic studies show that modulating SARM1 activity can protect motor axons in models of ALS, suggesting therapeutic potential[@ferraiuolo2015]. [@gilley2010]

Alzheimer's Disease

Axonal dystrophy and neurite degeneration occur in early Alzheimer's disease, with SARM1 potentially amplifying these processes secondary to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology. SARM1 inhibitors may provide neuroprotection by preserving axonal integrity[@xie2019]. [@geisler2019]

Parkinson's Disease

Dopaminergic [neurons](/entities/neurons) in the substantia nigra exhibit particular vulnerability to axonal degeneration in Parkinson's disease. SARM1 inhibition offers a neuroprotective strategy to preserve dopaminergic axonal projections[@cheng2011]. [@bratkowski2020]

Traumatic Brain Injury and Stroke

Primary axotomy in traumatic brain injury and ischemic stroke triggers SARM1-dependent axon degeneration. SARM1 inhibitors administered after injury can significantly improve functional outcomes in preclinical models[@yang2015]. [@mcguinness2024]

Glaucoma

Retinal ganglion cell axon degeneration in glaucoma involves SARM1 activation. Topical SARM1 inhibitor formulations are being developed for neuroprotection in glaucoma patients[@quigley2024].

Development Pipeline

Preclinical Stage

Multiple pharmaceutical companies have SARM1 inhibitor programs in preclinical development:

Small molecule NADase inhibitors: Targeting the catalytic TIR domain
Dominant-negative SARM1 constructs: Gene therapy approaches
AAV-delivered shRNA: Viral vector-mediated SARM1 knockdown

Clinical Candidates

While no SARM1 inhibitors have reached clinical trials as of 2025, several candidates are advancing toward IND-enabling studies:

Oral small molecules for chronic neuropathic conditions
Intravitreal formulations for retinal disorders
AAV gene therapy for inherited peripheral neuropathies

Key Research Findings

Genetic knockout protection: SARM1-/- mice show complete resistance to axon degeneration following injury[@gilley2010]

Therapeutic window: Pharmacological inhibitors can achieve neuroprotection when administered within hours of injury[@geisler2019]

Selectivity: First-generation inhibitors show good selectivity for SARM1 over related NADases[@bratkowski2020]

Combination potential: SARM1 inhibitors synergize with neuroprotective and anti-inflammatory agents[@mcguinness2024]

Cross-Links

[SARM1 and Programmed Axon Degeneration](/mechanisms/sarm1-programmed-axon-degeneration)
[SARM1 Gene](/genes/sarm1)
[SARM1 Protein](/proteins/sarm1-protein)
[NAD+ Metabolism in Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration)
[Treatments Index](/therapeutics)

External Links

[SARM1 Research Foundation](https://sarm1research.org/)
[ClinicalTrials.gov - Axon Degeneration](https://clinicaltrials.gov/)

Background

The study of Sarm1 Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Osterloh, J. M., et al., (2012). "dSarm/Sarm1 is required for activation of an injury-induced axon death pathway." Science, 337(6093), 481-484. [DOI (2012)](https://doi.org/10.1126/science.1223899)

[Unknown, Figley, M. D., & DiAntonio, A. (2020). "The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease." Current Opinion in Neurobiology, 63, 59-66. [DOI (2020)](https://doi.org/10.1016/j.conb.2020.02.012)

[Chaudhry, V., et al., (2024). "SARM1 Activation Contributes to Chemotherapy-Induced Peripheral Neuropathy." Annals of Neurology, 95(2), 280-295. [DOI (2024)](https://doi.org/10.1002/ana.26543)

[Chaudhry, V., et al., (2024). "Characterization of Novel SARM1 Inhibitors for the Treatment of Chemotherapy-Induced Peripheral Neuropathy." Biomedicines, 12(9), 2123. [DOI (2024)](https://doi.org/10.3390/biomedicines12092123)

[Ferraiuolo, L., et al., (2015). "Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis." Nature Reviews Neurology, 11(11), 651-662. [DOI (2015)](https://doi.org/10.1038/nrneurol.2015.170)

[Xie, Y., et al., (2019). "Axonal degeneration in Alzheimer's Disease: from phenomenology to mechanism." Acta Neuropathologica, 138(4), 567-588. [DOI (2019)](https://doi.org/10.1007/s00401-019-02023-x)

[Cheng, H. C., et al., (2011). "Axon injury and transneuronal degeneration in Parkinson disease." Brain Research, 1400, 93-99. [DOI (2011)](https://doi.org/10.1016/j.brainres.2011.05.050)

[Yang, J., et al., (2015). "Pathological Axon Degeneration Is Executed by SARM1 in a Co-culture System." Cellular and Molecular Neurobiology, 35(8), 1107-1116. [DOI (2015)](https://doi.org/10.1007/s10571-015-0223-5)

[Quigley, H. A., et al., (2024). "SARM1 Inhibition for Glaucoma Neuroprotection." Investigative Ophthalmology & Visual Science, 65(7), 3284. [DOI (2024)](https://doi.org/10.1167/iovs.65.7.3284)

[Unknown, Gilley, J., & Coleman, M. P. (2010). "Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons." PLoS Biology, 8(1), e1000300. [DOI (2010)](https://doi.org/10.1371/journal.pbio.1000300)

[Geisler, S., et al., (2019). "Gene therapy targeting SARM1 blocks pathological axon degeneration in mice." Journal of Experimental Medicine, 216(2), 294-303. [DOI (2019)](https://doi.org/10.1084/jem.20181040)

[Bratkowski, M., et al., (2020). "Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1." Cell Reports, 32(5), 107999. [DOI (2020)](https://doi.org/10.1016/j.celrep.2020.107999)

[McGuinness, H. Y., et al., (2024). "SARM1-Dependent Axon Degeneration: Nucleotide Signaling, Neurodegenerative Disorders, Toxicity, and Therapeutic Opportunities." The Neuroscientist, 30(4), 341-365. [DOI (2024)](https://doi.org/10.1177/10738584231162508)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving sarm1-inhibitors-neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

sarm1-inhibitors-neurodegeneration

SARM1 Inhibitors for Neurodegeneration

Introduction

Overview

SARM1 Inhibitors for Neurodegeneration

Introduction

Overview

Mechanism of Action

Therapeutic Applications

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease

Traumatic Brain Injury and Stroke

Glaucoma

Development Pipeline

Preclinical Stage

Clinical Candidates

Key Research Findings

Cross-Links

See Also

External Links

Background

References

Related Hypotheses

Pathway Diagram